Given the young age of one of the patients and hence the risk for misclassification of his tumor as an aggressive NUT carcinoma on the basis of NUT immunoexpression alone, we believe reporting these cases is of utmost relevance for the differential diagnosis of NUT-positive neoplasms in head and neck routine surgical pathology practice. The gene discussed is NUTM1; the disease is nut midline carcinoma.